Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives $12.25 Consensus Target Price from Analysts

Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) have received an average recommendation of “Moderate Buy” from the fifteen research firms that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, twelve have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $12.25.

Several research analysts have recently weighed in on the company. LADENBURG THALM/SH SH assumed coverage on Compass Therapeutics in a research report on Wednesday, July 1st. They issued a “buy” rating and a $5.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Compass Therapeutics in a research report on Friday, July 17th. Raymond James Financial cut Compass Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Tuesday, April 28th. Canaccord Genuity Group lowered their target price on Compass Therapeutics from $13.00 to $7.00 and set a “buy” rating for the company in a report on Tuesday, April 28th. Finally, HC Wainwright reissued a “buy” rating and issued a $24.00 price target on shares of Compass Therapeutics in a research note on Monday, April 27th.

Institutional Trading of Compass Therapeutics

Several hedge funds have recently modified their holdings of CMPX. Wealthcare Advisory Partners LLC acquired a new position in shares of Compass Therapeutics during the 2nd quarter valued at $134,000. Wealthcare Capital Partners LLC acquired a new stake in Compass Therapeutics in the second quarter worth $43,000. Seven Fleet Capital Management LP grew its holdings in Compass Therapeutics by 65.4% in the first quarter. Seven Fleet Capital Management LP now owns 940,538 shares of the company’s stock worth $4,975,000 after purchasing an additional 371,791 shares during the period. DV Trading LLC increased its stake in Compass Therapeutics by 1,649.8% in the first quarter. DV Trading LLC now owns 423,566 shares of the company’s stock valued at $2,241,000 after purchasing an additional 399,359 shares in the last quarter. Finally, Parallel Advisors LLC bought a new stake in Compass Therapeutics in the first quarter valued at $28,000. Institutional investors own 68.43% of the company’s stock.

Compass Therapeutics Stock Up 0.5%

CMPX opened at $2.08 on Tuesday. Compass Therapeutics has a twelve month low of $1.61 and a twelve month high of $6.88. The company has a fifty day moving average of $2.12 and a 200-day moving average of $4.08. The stock has a market cap of $374.59 million, a PE ratio of -5.07 and a beta of 0.90.

Compass Therapeutics (NASDAQ:CMPX) last released its earnings results on Tuesday, May 5th. The company reported ($0.10) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.10). Sell-side analysts anticipate that Compass Therapeutics will post -0.42 EPS for the current fiscal year.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical?stage biotechnology company dedicated to the discovery and development of novel immuno?oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti?tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47?SIRP? pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.